Nanoscale imaging of bacterial infections by sphingolipid expansion microscopy.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
02 12 2020
Historique:
received: 08 06 2020
accepted: 05 11 2020
entrez: 3 12 2020
pubmed: 4 12 2020
medline: 16 12 2020
Statut: epublish

Résumé

Expansion microscopy (ExM) enables super-resolution imaging of proteins and nucleic acids on conventional microscopes. However, imaging of details of the organization of lipid bilayers by light microscopy remains challenging. We introduce an unnatural short-chain azide- and amino-modified sphingolipid ceramide, which upon incorporation into membranes can be labeled by click chemistry and linked into hydrogels, followed by 4× to 10× expansion. Confocal and structured illumination microscopy (SIM) enable imaging of sphingolipids and their interactions with proteins in the plasma membrane and membrane of intracellular organelles with a spatial resolution of 10-20 nm. As our functionalized sphingolipids accumulate efficiently in pathogens, we use sphingolipid ExM to investigate bacterial infections of human HeLa229 cells by Neisseria gonorrhoeae, Chlamydia trachomatis and Simkania negevensis with a resolution so far only provided by electron microscopy. In particular, sphingolipid ExM allows us to visualize the inner and outer membrane of intracellular bacteria and determine their distance to 27.6 ± 7.7 nm.

Identifiants

pubmed: 33268771
doi: 10.1038/s41467-020-19897-1
pii: 10.1038/s41467-020-19897-1
pmc: PMC7710728
doi:

Substances chimiques

Ceramides 0
Hydrogels 0
omega-amino-ceramide 0

Banques de données

figshare
['10.6084/m9.figshare.13147955']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6173

Références

Sci Rep. 2017 Dec 15;7(1):17627
pubmed: 29247204
Nat Commun. 2020 Jul 7;11(1):3388
pubmed: 32636396
ACS Nano. 2019 Feb 26;13(2):2143-2157
pubmed: 30715853
Nat Methods. 2019 Jan;16(1):33-41
pubmed: 30573813
Cell Microbiol. 2020 May;22(5):e13136
pubmed: 31677225
Front Cell Dev Biol. 2019 Sep 19;7:203
pubmed: 31608278
Mol Microbiol. 2016 Jan;99(1):151-71
pubmed: 26374382
J Immunol. 2016 May 1;196(9):3951-62
pubmed: 27036914
Cell Microbiol. 2017 Oct;19(10):
pubmed: 28544656
BMC Microbiol. 2008 Jan 09;8:5
pubmed: 18182115
Nat Commun. 2018 Jan 3;9(1):45
pubmed: 29298975
Antimicrob Agents Chemother. 2012 Mar;56(3):1157-61
pubmed: 22155833
Nat Methods. 2016 Aug;13(8):679-84
pubmed: 27376770
EMBO J. 1996 Mar 1;15(5):964-77
pubmed: 8605892
Proc Natl Acad Sci U S A. 2011 Jun 21;108(25):10284-9
pubmed: 21628561
Prog Lipid Res. 2007 May-Jul;46(3-4):161-70
pubmed: 17490747
PLoS Pathog. 2011 Sep;7(9):e1002198
pubmed: 21909260
Front Cell Infect Microbiol. 2019 Aug 09;9:276
pubmed: 31448242
Chem Commun (Camb). 2016 Jun 30;52(55):8612-8614
pubmed: 27327378
J Microsc. 2000 May;198(Pt 2):82-7
pubmed: 10810003
Chem Commun (Camb). 2017 Jun 22;53(51):6836-6839
pubmed: 28597878
Nat Biotechnol. 2016 Sep;34(9):987-92
pubmed: 27376584
Infect Drug Resist. 2018 Apr 11;11:523-530
pubmed: 29695921
Angew Chem Int Ed Engl. 2017 May 22;56(22):6131-6135
pubmed: 28379629
Nat Methods. 2019 Jan;16(1):71-74
pubmed: 30559430
Nat Commun. 2020 Jun 26;11(1):3222
pubmed: 32591508
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
PLoS Pathog. 2011 Jun;7(6):e1002092
pubmed: 21731489
J Biol Chem. 2002 Jul 19;277(29):25847-50
pubmed: 12011103
ACS Nano. 2020 Jul 28;14(7):7860-7867
pubmed: 32176475
Nat Rev Microbiol. 2004 Jul;2(7):530-1
pubmed: 15248311
Cell Microbiol. 2015 Feb;17(2):241-53
pubmed: 25224994
Biol Chem. 2018 Sep 25;399(10):1157-1168
pubmed: 29908120
Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(4):426-37
pubmed: 20431265
Nat Methods. 2016 Jun;13(6):485-8
pubmed: 27064647
Front Cell Dev Biol. 2019 Oct 04;7:223
pubmed: 31637241
J Cell Biol. 2014 May 26;205(4):591-606
pubmed: 24862576
PLoS Biol. 2019 Oct 17;17(10):e3000268
pubmed: 31622337
Nat Cell Biol. 2019 Jan;21(1):72-84
pubmed: 30602772
J Immunol. 2007 Oct 1;179(7):4829-39
pubmed: 17878382
Trends Mol Med. 2007 Aug;13(8):327-36
pubmed: 17588815
Nat Protoc. 2019 Mar;14(3):832-863
pubmed: 30778205
Chem Rev. 2017 Jun 14;117(11):7478-7509
pubmed: 28287710
Science. 2015 Jan 30;347(6221):543-8
pubmed: 25592419
Front Cell Infect Microbiol. 2020 May 12;10:215
pubmed: 32477967
Nat Methods. 2017 Jun;14(6):593-599
pubmed: 28417997
J Mol Med (Berl). 2004 Jun;82(6):357-63
pubmed: 15069600
PLoS Biol. 2017 Dec 19;15(12):e2004303
pubmed: 29257832

Auteurs

Ralph Götz (R)

Department of Biotechnology and Biophysics, Biocenter, Julius-Maximilians-Universität Würzburg, Am Hubland, 97074, Würzburg, Germany.

Tobias C Kunz (TC)

Department of Microbiology, Biocenter, Julius-Maximilians-Universität Würzburg, Am Hubland, 97074, Würzburg, Germany.

Julian Fink (J)

Institute for Organic Chemistry, Julius-Maximilians-Universität Würzburg, Am Hubland, 97074, Würzburg, Germany.

Franziska Solger (F)

Department of Microbiology, Biocenter, Julius-Maximilians-Universität Würzburg, Am Hubland, 97074, Würzburg, Germany.

Jan Schlegel (J)

Department of Biotechnology and Biophysics, Biocenter, Julius-Maximilians-Universität Würzburg, Am Hubland, 97074, Würzburg, Germany.

Jürgen Seibel (J)

Institute for Organic Chemistry, Julius-Maximilians-Universität Würzburg, Am Hubland, 97074, Würzburg, Germany.

Vera Kozjak-Pavlovic (V)

Department of Microbiology, Biocenter, Julius-Maximilians-Universität Würzburg, Am Hubland, 97074, Würzburg, Germany.

Thomas Rudel (T)

Department of Microbiology, Biocenter, Julius-Maximilians-Universität Würzburg, Am Hubland, 97074, Würzburg, Germany. thomas.rudel@biozentrum.uni-wuerzburg.de.

Markus Sauer (M)

Department of Biotechnology and Biophysics, Biocenter, Julius-Maximilians-Universität Würzburg, Am Hubland, 97074, Würzburg, Germany. m.sauer@uni-wuerzburg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH